Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224844 | 1.00 | RARB (0.40) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL7219284 | 1.00 | RARB (0.40) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL6477990 | 1.00 | RARB (0.40) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL9278406 | 1.00 | RARB (0.40) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL7222773 | 0.98 | RARB (0.41) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL6476866 | 0.92 | LMNA (0.52) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL30849949 | 0.92 | LMNA (0.52) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL6477852 | 0.92 | LMNA (0.52) | RARBNAAALMNAKDM4CKDM4A | |
| SCHEMBL4675873 | 0.91 | BLM (0.39) | RARBLMNABLMALDH1A1ACHE | |
| SCHEMBL6472477 | 0.89 | FAAH (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529166-A | Polymer dispersant containing sulfonic group, color paste and application thereof | 北京云基科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3839028-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4386075-A2 | CLEANING PRODUCT | The Procter & Gamble Company (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834627-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834629-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4124651-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-6667285-B1 | Branched-chain carboxylic acid monoalkyl ester with outstanding hydrolytic stability | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| EP-1225213-A1 | LUBRICATING OIL FOR REFRIGERATOR, HYDRAULIC FLUID COMPOSITION FOR REFRIGERATOR AND METHOD FOR LUBRICATION OF REFRIGERATOR | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | RARB 3241/4885NAAA 2240/4885LMNA 1480/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | RARB 566/4885NAAA 3246/4885LMNA 3173/4885 |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | RARB 3526/4885NAAA 3034/4885LMNA 3084/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | RARB 2921/4885NAAA 2581/4885LMNA 2534/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | RARB 2027/4885NAAA 4306/4885LMNA 2696/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | RARB 612/4885NAAA 3630/4885LMNA 3171/4885 |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | RARB 2921/4885NAAA 2581/4885LMNA 2534/4885 |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | RARB 3548/4885NAAA 3924/4885LMNA 3215/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | RARB 1987/4885NAAA 3681/4885LMNA 1341/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | RARB 3393/4885NAAA 1129/4885LMNA 1302/4885 |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | GPER1, PSMA3, ESR2 | RARB 1125/4885NAAA 4347/4885LMNA 2853/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | RARB 2921/4885NAAA 2581/4885LMNA 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.